U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

Sebacia, Inc., a privately held, commercial stage dermatology andaesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has grantedclearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstratedclinical efficacy and safety of Sebacia Microparticles, and its 510(k) submission to the FDA in June 2018.